Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1177/1756283X15580743 http://scihub22266oqcxt.onion/10.1177/1756283X15580743 C4530428!4530428!26327919     free     free     free       Therap+Adv+Gastroenterol 2015 ; 8 (5): 285-97 Nephropedia Template TP {{tp|p=26327919|t=2015. Management of regorafenib-related toxicities: a review |pdf=|usr=}}{{26327919}} gab.com Text Management of regorafenib-related toxicities: a review JO: Therap Adv Gastroenterol http://www.kidney.de/pget.php?&tw=1&pmid=26327919 #FOAvip Regorafenib (Stivarga, BAY 73-4506; Bayer Pharma AG, Berlin, Germany) is an oral multikinase inhibitor that targets the angiogenic tumor microenvironment and oncogenic kinases including vascular endothelial growth factor receptor 2 (VEGFR2), VEGFR1, VEGFR3, fibroblast growth factor receptor 1 (FGFR1), RAF, KIT, RET and BRAF. Its antiangiogenic effect is greater than that of its related drug, sorafenib. Regorafenib has been approved by the US Food and Drug Administration (FDA) for the treatment of metastatic colorectal cancer (mCRC) in patients who have failed treatment with fluoropyrimidine, oxaliplatin and irinotecan based chemotherapy, an anti-VEGF therapy and, if KRAS wild type, an anti-EGFR therapy. The FDA based this approval on data from the CORRECT trial, which showed the efficacy of regorafenib compared with placebo. The most common grade 3?4 adverse reactions with the drug are hand foot skin reactions (HFSR), diarrhea, hypertension and fatigue. This review discusses the efficacy data, and the incidence and management of regorafenib?s toxicities. Twit Text FOAVip Management of regorafenib-related toxicities: a review ????Therap Adv Gastroenterol http://www.kidney.de/pget.php?&tw=1&pmid=26327919 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26327919 #FOAvip English Wikipedia <ref>{{Cite pmid|26327919}}</ref> Management of regorafenib-related toxicities: a review #MMPMID26327919 Krishnamoorthy SK; Relias V; Sebastian S; Jayaraman V; Saif MW Therap Adv Gastroenterol 2015[Sep]; 8 (5): 285-97 PMID26327919show ga Regorafenib (Stivarga, BAY 73-4506; Bayer Pharma AG, Berlin, Germany) is an oral multikinase inhibitor that targets the angiogenic tumor microenvironment and oncogenic kinases including vascular endothelial growth factor receptor 2 (VEGFR2), VEGFR1, VEGFR3, fibroblast growth factor receptor 1 (FGFR1), RAF, KIT, RET and BRAF. Its antiangiogenic effect is greater than that of its related drug, sorafenib. Regorafenib has been approved by the US Food and Drug Administration (FDA) for the treatment of metastatic colorectal cancer (mCRC) in patients who have failed treatment with fluoropyrimidine, oxaliplatin and irinotecan based chemotherapy, an anti-VEGF therapy and, if KRAS wild type, an anti-EGFR therapy. The FDA based this approval on data from the CORRECT trial, which showed the efficacy of regorafenib compared with placebo. The most common grade 3?4 adverse reactions with the drug are hand foot skin reactions (HFSR), diarrhea, hypertension and fatigue. This review discusses the efficacy data, and the incidence and management of regorafenib?s toxicities. äManagement of regorafenib-related toxicities: a review (epmc).pdf DeepDyve Pubget Overpricing